Restored immunosuppressive effect of mesenchymal stem cells on b cells after olfactory 1/early B cell factor-associated zinc-finger protein down-regulation in patients with systemic lupus erythematosus

Arthritis and Rheumatology

Volumn 66, Issue 12, 2014, Pages 3413-3423

  Feng, Xuebing ^a   Che, Nan ^a   Liu, Yan ^a   Chen, Haifeng ^a   Wang, Dandan ^a   Li, Xia ^a   Chen, Weiwei ^a   Ma, Xiaolei ^a   Hua, Bingzhu ^a   Gao, Xiang ^b   Tsao, Betty P ^c   Sun, Lingyun ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 21; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; OLFACTORY 1 EARLY B CELL FACTOR ASSOCIATED ZINC FINGER PROTEIN; SMALL INTERFERING RNA; SYNDECAN 1; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; CYTOKINE; DNA BINDING PROTEIN; OAZ PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; BONE MARROW; CELL DIFFERENTIATION; CELL PROLIFERATION; COCULTURE; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; IMMUNOGLOBULIN PRODUCTION; IMMUNOMODULATION; LEUKOCYTE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; WESTERN BLOTTING; ANIMAL; CASE CONTROL STUDY; CYTOLOGY; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MESENCHYMAL STROMA CELL; SPLEEN;

ANIMALS; ANTIBODIES, ANTINUCLEAR; B-LYMPHOCYTES; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYTOKINES; DNA-BINDING PROTEINS; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNE TOLERANCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MESENCHYMAL STROMAL CELLS; MICE; RNA, MESSENGER; SPLEEN;

EID: 84912004805     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38879     Document Type: Article

References (38)

1. Dorner T, Giesecke C, Lipsky PE,. Mechanisms of B cell autoimmunity in SLE. Arthritis Res Ther 2011; 13: 243.
2. Feng XB, Shen N, Chen SL, Qian J, Wu H, Bao CD, et al. Susceptibility gene of systemic lupus erythematosus in 16q12 in Chinese cohort. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2003; 20: 27-30. In Chinese.
3. Feng X, Li R, Huang J, Zhang H, Zhu L, Hua B, et al. Olf1/EBF associated zinc finger protein interfered with antinuclear antibody production in patients with systemic lupus erythematosus. Arthritis Res Ther 2010; 12: R59.
4. Carsetti R,. The development of B cells in the bone marrow is controlled by the balance between cell-autonomous mechanisms and signals from the microenvironment. J Exp Med 2000; 191: 5-8.
5. Prockop DJ,. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997; 276: 71-4.
6. Stagg J,. Immune regulation by mesenchymal stem cells: two sides to the coin. Tissue Antigens 2007; 69: 1-9.
7. Comoli P, Ginevri F, Maccario R, Avanzini MA, Marconi M, Groff A, et al. Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation. Nephrol Dial Transplant 2008; 23: 1196-202.
8. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107: 367-72.
9. Asari S, Itakura S, Ferreri K, Liu CP, Kuroda Y, Kandeel F, et al. Mesenchymal stem cells suppress B-cell terminal differentiation. Exp Hematol 2009; 37: 604-15.
10. Tabera S, Perez-Simon JA, Diez-Campelo M, Sanchez-Abarca LI, Blanco B, Lopez A, et al. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Haematologica 2008; 93: 1301-9.
11. Che N, Li X, Zhou S, Liu R, Shi D, Lu L, et al. Umbilical cord mesenchymal stem cells suppress B-cell proliferation and differentiation. Cell Immunol 2012; 274: 46-53.
12. Sun LY, Zhang HY, Feng XB, Hou YY, Lu LW, Fan LM,. Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 2007; 16: 121-8.
13. Sun L, Wang D, Liang J, Zhang H, Feng X, Wang H, et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum 2010; 62: 2467-75.
14. Zhou K, Zhang H, Jin O, Feng X, Yao G, Hou Y, et al. Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell Mol Immunol 2008; 5: 417-24.
15. Carrion FA, Figueroa FE,. Mesenchymal stem cells for the treatment of systemic lupus erythematosus: is the cure for connective tissue diseases within connective tissue? Stem Cell Res Ther 2011; 2: 23.
16. kip1 mRNA in early G1 phase and is required for cell-cycle progression. Oncogene 2007; 26: 5772-83.
17. Li RL, Huang J, Sun LY, Feng XB,. Gene expression of OAZ pathway in the patients of systemic lupus erythematosus. Zhonghua Yi Xue Za Zhi 2009; 89: 2068-71. In Chinese.
18. Peng Y, Kang Q, Luo Q, Jiang W, Si W, Liu BA, et al. Inhibitor of DNA binding/differentiation helix-loop-helix proteins mediate bone morphogenetic protein-induced osteoblast differentiation of mesenchymal stem cells. J Biol Chem 2004; 279: 32941-9.
19. Rafei M, Hsieh J, Fortier S, Li M, Yuan S, Birman E, et al. Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood 2008; 112: 4991-8.
20. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
21. Feng X, Zou Y, Pan W, Wang X, Wu M, Zhang M, et al. Prognostic indicators of hospitalized patients with systemic lupus erythematosus: a large retrospective multicenter study in China. J Rheumatol 2011; 38: 1289-95.
22. Diamanti AP, Rosado MM, Carsetti R, Valesini G,. B cells in SLE: different biological drugs for different pathogenic mechanisms. Autoimmun Rev 2007; 7: 143-8.
23. Dorner T, Jacobi AM, Lee J, Lipsky PE,. Abnormalities of B cell subsets in patients with systemic lupus erythematosus. J Immunol Methods 2011; 363: 187-97.
24. Jacob N, Stohl W,. Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future. Autoimmunity 2010; 43: 84-97.
25. La Cava A,. Targeting B cells with biologics in systemic lupus erythematosus. Expert Opin Biol Ther 2010; 10: 1555-61.
26. Lo MS, Tsokos GC,. Treatment of systemic lupus erythematosus: new advances in targeted therapy. Ann N Y Acad Sci 2012; 1247: 138-52.
27. Abumaree M, Al Jumah M, Pace RA, Kalionis B,. Immunosuppressive properties of mesenchymal stem cells. Stem Cell Rev 2012; 8: 375-92.
28. Ma X, Che N, Gu Z, Huang J, Wang D, Liang J, et al. Allogenic mesenchymal stem cell transplantation ameliorates nephritis in lupus mice via inhibition of B-cell activation. Cell Transplant 2013; 22: 2279-90.
29. Shim S, Bae N, Han JK,. Bone morphogenetic protein-4-induced activation of Xretpos is mediated by Smads and Olf-1/EBF associated zinc finger (OAZ). Nucleic Acids Res 2002; 30: 3107-17.
30. Brayer KJ, Kulshreshtha S, Segal DJ,. The protein-binding potential of C2H2 zinc finger domains. Cell Biochem Biophys 2008; 51: 9-19.
31. Hata A, Seoane J, Lagna G, Montalvo E, Hemmati-Brivanlou A, Massague J,. OAZ uses distinct DNA- and protein-binding zinc fingers in separate BMP-Smad and Olf signaling pathways. Cell 2000; 100: 229-40.
32. Ku M, Howard S, Ni W, Lagna G, Hata A,. OAZ regulates bone morphogenetic protein signaling through Smad6 activation. J Biol Chem 2006; 281: 5277-87.
33. Huang S, Laoukili J, Epping MT, Koster J, Holzel M, Westerman BA, et al. ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Cancer Cell 2009; 15: 328-40.
34. Holzel M, Huang S, Koster J, Ora I, Lakeman A, Caron H, et al. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 2010; 142: 218-29.
35. Chaki M, Airik R, Ghosh AK, Giles RH, Chen R, Slaats GG,. et al. Exome capture reveals ZNF423 and CEP164 mutations, linking renal ciliopathies to DNA damage response signaling. Cell 2012; 150: 533-48.
36. Jaager K, Neuman T,. Human dermal fibroblasts exhibit delayed adipogenic differentiation compared with mesenchymal stem cells. Stem Cells Dev 2011; 20: 1327-36.
37. De Miguel MP, Fuentes-Julian S, Blazquez-Martinez A, Pascual CY, Aller MA, Arias J, et al. Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med 2012; 12: 574-91.
38. Guilloton F, Caron G, Menard C, Pangault C, Ame-Thomas P, Dulong J, et al. Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes. Blood 2012; 119: 2556-67.